Optibiotix Health Share Discussion Threads

[imnotlong] 11/7/2017 07:29

News filler due to lack of contracts. Ask how long ago these taste trails were actually undertaken. Not recently is my guess, but news released today as they have no contract news.

"Achieve this by combining early generation of revenues whilst working on the medium to long-term strategic commercial partnerships." translated from Pers words this means no big deals soon.

[rafboy] 11/7/2017 07:08

Wow, good news and this could really change lives for the better.

[trotterstrading] 11/7/2017 07:05

Yes incredible improvement in sweetness equivalency!

[someuwin] 11/7/2017 07:02

OptiBiotix Health plc

("OptiBiotix" or the Company")



SweetBiotix® development: Results of human taste study

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces successful human taste studies in its SweetBiotix® product development programme. The programme has been designed to develop sweet natural healthy fibres, called SweetBiotix®, which are not digested in the human gut, and hence calorie free.

The study was carried out by The Flavour and Sensory Science Centre at the University of Reading who tested six customised oligosaccharides developed from high intensity sweeteners which were compared to sucrose. The study used a trained expert panel of ten experienced panellists and showed:-

· The customised oligosaccharides showed sweetness of between 140X and 223X that of sucrose at equivalent concentrations

· Customised oligosaccharides derived from Stevia showed a large reduction in bitterness whilst not affecting its sweetness



The results of this independent study provide proof of product concept for a natural, low calorie, SweetBiotix®. This is an innovative concept which has the potential to address public health concerns over the impact of sugar on obesity, with the prospect of replacing 'unhealthy' sugars in existing products with low calorie, healthy non-digestible fibres, trademarked as SweetBiotix®.



Given the global sweetener market, currently dominated by sugar, is forecast to reach $112bn by 2022 (Mordor Intelligence, 2017), the Company are filing additional patents to add a further layer of protection to the existing intellectual property portfolio to protect their inventions and fully exploit the commercial potential.



Stephen O'Hara, CEO of OptiBiotix, commented: "We are really pleased with the results of this study which opens up opportunities for the development of a range of natural sweet prebiotic fibres which can be used to replace sugar in food and beverages. These may be classified as dietary fibres, which from an industry and consumer perspective, creates the prospect of substituting high calorie sugars with sweet healthy fibres. With growing public and political concerns over traditional sugars and artificial sweeteners OptiBiotix is leading research in an area of growing industry interest."

[john henry] 11/7/2017 02:36

The share price remains under the spell of a huge declining wedge from NOV 2015. After a brief spell out of the pattern its influence is strong. Floor is 60p, resistance line currently 72.5p im expecting a retest of 60p before another attempt. Short term, 8 EMA will play its part as resistance.
There is also a medium term rising wedge in play from Oct 2016 with a price target of 100p.
60p support will determine the next direction.
Whatever news is announced it needs to change market sentiment towards the company.

[john henry] 10/7/2017 23:16

HLH scheduled release is still on for the end of JULY ( S OHara email) also looking forward to the announcement of combination formulations which will be more potent. Hopefully get to trial as my family suffer through the use of statins.

[rickyvee] 10/7/2017 21:09

Per sounds like Ohara. Heard it all before.

[parob] 10/7/2017 20:09

Per's recent LinkedIn status update:'VitaFoods generated a lot of commercial interest internationally with a wealth of conversations ongoing in different areas and different levels of progress, and it is exciting to be part of OptiBiotix to develop the company commercially and to align our commercial strategy with the right partners in different areas and territories as the company matures commercially. It will be all about creating the best value for our investors. Achieve this by combining early generation of revenues whilst working on the medium to long-term strategic commercial partnerships. 2017 looks to be an exciting year in the area of Microbiome modulation and the new generation targeted Probiotics will undoubtedly take its space in the future of health interventions.'

[elrico] 10/7/2017 18:58

Factors such as increased focus on human microbiome therapy, growing demand for human microbiomes as new validated targets for drug development, and the need for early disease detection and diagnosis are expected to drive the growth of the human microbiome market.

New Research Report on Human Microbiome presents an in-depth study of the market. Providing a brief history about the market, the report analyses the entire value chain of the market and points out the key drivers and restraints affecting the growth of the market during the forecast period. The report also analyses the market attractiveness and the effect of Porter’s Five Forces on the various factors governing the overall market.

By product, the global human microbiome market is classified into probiotics, prebiotics, foods, medical foods, supplements, diagnostic devices, and drugs. The expectation that microbiome products, which will aid in the early-stage treatment of chronic diseases and various disorders, will be available in the market in the future is a key driver for the growth of this market.

For Sample copy of this Report:

Companies Profiled in this Report Includes, Ritter Pharmaceuticals, Inc., E. I. du Pont de Nemours and Company, ViThera Pharmaceuticals, Metabiomics Corp., ActoGeniX, Optibiotix Health Plc, Vedanta Biosciences, Inc., MicroBiome Therapeutics, LLC, Second Genome, Inc., ENTEROME Bioscience, Yakult Honsha Co., Ltd., Osel, Inc., AvidBiotics, Rebiotix Inc., Merck & Co., Inc. and Seres Therapeutics.

[onedayrodders] 10/7/2017 17:03

Yes Neft and news never substantial enough with ££ numbers to sustain any short term rise.

Hopefully SOH's latest comments will mena the next newsflow will change all that.

[bernieboy] 10/7/2017 16:20

Net it is true that it is both news and sentiment driven. But as I said earlier recently one of the RNSs did come along around lunchtime. So even if they don't appear first thing in the morning doesn't mean that's it for the day. As we all know a multitude of very positive RNSs will start to drop very soon. Once the first comes I suspect they will be like London buses !

[neftanikoff] 10/7/2017 15:59

I think as soon as 7.00 am comes and goes every week day, without a RNS, you just know what is going to happen. This share is just so dependent on news, it's untrue.

[rafboy] 10/7/2017 15:49

Good to see a 30k share buy just now. Not me unfortunately.

[rafboy] 10/7/2017 15:29

Think we need a game of stop the drop.

[bernieboy] 10/7/2017 11:19

Could come anytime. One of the recent RNSs was out at lunchtime....

[slartybartfaster] 10/7/2017 07:13

Not today.

[trotterstrading] 09/7/2017 21:38

News this week? Could be.. I'm going for a YES! :0)

[diamond fibre] 09/7/2017 18:10

I do! JJ13, but don't tell hubby! I will get a rise next week? Lol

[joyjoy13] 09/7/2017 16:01

Diamond!
Something you want to tell me?

Have good holiday and hopefully on your return share price might of bucked up a bit...but great buying opportunity that's for sure.

[parob] 08/7/2017 21:58

Well done Diamond. Buy whilst it's quiet and cheap. So obvious this is going to bounce over the next few sessions IMO. I'm buying a few for my godson on Monday.

[diamond fibre] 08/7/2017 21:54

Up in Yorkshire to see my brother, hope all goes well next week! DIAMOND.

[diamond fibre] 08/7/2017 21:45

Blimey only 9000 shares purchased on Friday, and 5000 was mine, still like my lover jj13, we will have a good time when the boat comes in! Lol. DIAMOND.

[zebbo] 08/7/2017 18:52

Not a big believer in charts. May be ok for high volume, liquid stocks that are bot traded. Basically charts will tell you what you want them to IMHO.
However most people know that anyway. Its news flow is the lifeblood of many AIM stocks, not chart indicators.

[parob] 08/7/2017 17:30

Go for it blueball!

'Bear market rallies may be vicious reversals, giving hard times to those holding short positions.'



International registration for the slimbiome trade mark accepted this past week (3/7/17).